Biorce Secures $52M to Revolutionize Clinical Trials with AI: Cutting Costs by 50% and Saving Lives

The clinical trial industry is on the cusp of a significant transformation, thanks to Biorce, a Barcelona-based HealthTech company that has just closed a €43.8 million Series A round. This funding will support the company's international expansion, hiring, and product development, with the ultimate goal of making clinical trials faster, more reliable, and accessible.



Biorce's mission to fix the clinical trial industry is timely, given that these trials take nearly 11 years and cost €5.2 billion to bring a drug to market. The company aims to slash these costs by over 50% and help life-saving treatments reach patients sooner. Clinical trials management represents an estimated €101.2 billion in global annual spend, with 57% of trials facing costly protocol amendments that add months of delay.



The traditional model of clinical trials is plagued by inefficiencies, with each protocol amendment typically halting patient recruitment for an average of six weeks and adding between €500k and €1 million in costs. Biorce's solution, Aika, is a native AI platform that reduces clinical trial preparation timelines and protocol amendments, accelerating the development of new therapies by up to 50%. Aika has been built upon a proprietary data foundation of around 1 million clinical trials and enables pharmaceutical companies, biotech firms, and CROs to design better trials faster, without compromising scientific rigour or patient safety.



For everyday users, this could mean faster access to life-saving treatments. From an industry perspective, Biorce's AI platform streamlines protocol development, site selection, and feasibility assessment, with the aim of reducing complexity, accelerating timelines, and improving operational efficiency. The implications extend beyond the pharmaceutical industry, as Biorce's technology has the potential to transform the way clinical trials are conducted, making them more efficient, cost-effective, and patient-centric.



The fresh capital will enable Biorce to support its international expansion and accelerate product development, further solidifying its position as a leader in the HealthTech and AI ecosystem. With Aika already in use across multiple therapeutic areas, including oncology, neurology, and rare diseases, Biorce is poised to make a significant impact on the clinical trial industry.



The company's 'human-in-the-loop' approach ensures that experts stay in control, with every Aika recommendation coming with complete documentation that can be defended before any regulatory authority. This approach sets Biorce apart from other AI solutions in the pharmaceutical industry, which often require users to trust algorithms without explanation.



As the clinical trial industry continues to evolve, Biorce is at the forefront of this transformation. With its innovative AI platform, Aika, and its commitment to making clinical trials faster, more reliable, and accessible, Biorce is poised to revolutionize the industry and save lives.



The significance of Biorce's funding cannot be overstated. The company has raised a total of over €50.6 million in funding, with the latest Series A round being the largest in the Iberian HealthTech and AI ecosystem to date. This investment is a strong validation of Biorce's technology, team, and mission, and will enable the company to accelerate its growth and expansion.



In conclusion, Biorce's $52 million funding is a significant milestone in the company's mission to transform the clinical trial industry. With its innovative AI platform, Aika, and its commitment to making clinical trials faster, more reliable, and accessible, Biorce is poised to make a significant impact on the industry and save lives.